Targeted Therapy and Evolving Research: Where Are We Winning and Losing in Chronic Myeloid Leukemia?

Drs Michael J. Mauro and Ehab Atallah discuss current chronic myeloid leukemia research, where the US stands in comparison with the world, and the important work being conducted by the Cure CML Consortium.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989025). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Chronic Myelogenous Leukemia (CML) https://emedicine.medscape.com/article/199425-overview

Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/

BCR-ABL Fusion Gene https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bcr-abl-fusion-gene

Trastuzumab/Hyaluronidase (Rx) https://reference.medscape.com/drug/herceptin-hylecta-trastuzumab-hyaluronidase-1000345

H. Jean Khoury Cure CML Consortium https://curecml.org/

Genetics, Philadelphia Chromosome https://www.ncbi.nlm.nih.gov/books/NBK560689/

National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Leukemia — Chronic Myeloid Leukemia (CML) https://seer.cancer.gov/statfacts/html/cmyl.html

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33180106/

Treatment-free Remission: The New Goal in CML Therapy https://pubmed.ncbi.nlm.nih.gov/34618317/

Monitoring Molecular Response in Chronic Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/20960522/

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation https://clinicaltrials.gov/ct2/show/NCT04838041

Asciminib https://reference.medscape.com/drug/scemblix-asciminib-4000255

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors https://clinicaltrials.gov/ct2/show/NCT03610971

Ruxolitinib (Rx) https://reference.medscape.com/drug/jakafi-ruxolitinib-999703

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase https://clinicaltrials.gov/ct2/show/NCT05143840

ATP-competitive Inhibitors Modulate the Substrate Binding Cooperativity of a Kinase by Altering Its Conformational Entropy https://pubmed.ncbi.nlm.nih.gov/35905186/

The Specificity of Asciminib, a Potential Treatment for Chronic Myeloid Leukemia, as a Myristate-pocket Binding ABL Inhibitor and Analysis of Its Interactions With Mutant Forms of BCR-ABL1 Kinase https://pubmed.ncbi.nlm.nih.gov/33096322/

Ponatinib (Rx) https://reference.medscape.com/drug/iclusig-ponatinib-999800

Accelerated Phase Chronic Myelogenous Leukemia https://www.cancer.gov/publications/dictionaries/cancer-terms/def/accelerated-phase-chronic-myelogenous-leukemia

Acute Myeloid Leukemia https://emedicine.medscape.com/article/197802-overview

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/30955853/

International Chronic Myeloid Leukemia Foundation https://www.cml-foundation.org/